Men in Quebec are one step closer to accessing Xofigo, for the treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease, thanks to a recent announcement by the Quebec government.
Xofigo will be added to the hospital drug list, giving hospitals the ability to provide patients with this new treatment option.
Bone metastases can significantly impact a patient’s quality of life, causing severe pain and compromising the structure of the bone, which can result in increased fractures. Bone metastases are the main cause of death in patients with metastatic castration-resistant prostate cancer.
Xofigo, or radium Ra 223 dichloride, is a therapeutic alpha particle-emitting radiopharmaceutical with targeted anti-tumor effect on bone metastases. Clinical studies showed that Xofigo can extend patient lives for about 3.6 months, while improving their quality of life.
For more information about Xofigo and bone metastases, speak to your physician.
